HCW Biologics Inc. (HCWB) stock
HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.75+0.01 (+1.90%)
Close on Nov 20, 2026Market cap $1.38MP/E –Yield –
HCW Biologics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
HCW Biologics's operating income for the twelve months ending Jun 30, 2026 was -$7.68M. For fiscal 2025 it was -$13.16M. The highest annual figure on record is -$5.82M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.16M | – |
| FY2024 | Dec 31, 2024 | -$29.46M | – |
| FY2023 | Dec 31, 2023 | -$25.72M | – |
| FY2022 | Dec 31, 2022 | -$15.08M | – |
| FY2021 | Dec 31, 2021 | -$13.37M | – |
| FY2020 | Dec 31, 2020 | -$5.82M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.17M | – |
| Q1 FY2026 | Mar 31, 2026 | $3.24M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.46M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.15M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.68M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.51M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.51M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.11M | -251.0% |
| Q3 FY2021 | Sep 30, 2021 | -$4.09M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.75M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.41M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.06M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.78M | – |
See a number that looks wrong?